236 related articles for article (PubMed ID: 15581591)
1. Modelling atypical CYP3A4 kinetics: principles and pragmatism.
Houston JB; Galetin A
Arch Biochem Biophys; 2005 Jan; 433(2):351-60. PubMed ID: 15581591
[TBL] [Abstract][Full Text] [Related]
2. Multisite kinetic models for CYP3A4: simultaneous activation and inhibition of diazepam and testosterone metabolism.
Kenworthy KE; Clarke SE; Andrews J; Houston JB
Drug Metab Dispos; 2001 Dec; 29(12):1644-51. PubMed ID: 11717184
[TBL] [Abstract][Full Text] [Related]
3. Multisite kinetic analysis of interactions between prototypical CYP3A4 subgroup substrates: midazolam, testosterone, and nifedipine.
Galetin A; Clarke SE; Houston JB
Drug Metab Dispos; 2003 Sep; 31(9):1108-16. PubMed ID: 12920166
[TBL] [Abstract][Full Text] [Related]
4. Sigmoidal kinetic model for two co-operative substrate-binding sites in a cytochrome P450 3A4 active site: an example of the metabolism of diazepam and its derivatives.
Shou M; Mei Q; Ettore MW; Dai R; Baillie TA; Rushmore TH
Biochem J; 1999 Jun; 340 ( Pt 3)(Pt 3):845-53. PubMed ID: 10359672
[TBL] [Abstract][Full Text] [Related]
5. Quinidine and haloperidol as modifiers of CYP3A4 activity: multisite kinetic model approach.
Galetin A; Clarke SE; Houston JB
Drug Metab Dispos; 2002 Dec; 30(12):1512-22. PubMed ID: 12433827
[TBL] [Abstract][Full Text] [Related]
6. CYP3A4 substrate selection and substitution in the prediction of potential drug-drug interactions.
Galetin A; Ito K; Hallifax D; Houston JB
J Pharmacol Exp Ther; 2005 Jul; 314(1):180-90. PubMed ID: 15784650
[TBL] [Abstract][Full Text] [Related]
7. Differential enantioselectivity and product-dependent activation and inhibition in metabolism of verapamil by human CYP3As.
Shen L; Fitzloff JF; Cook CS
Drug Metab Dispos; 2004 Feb; 32(2):186-96. PubMed ID: 14744940
[TBL] [Abstract][Full Text] [Related]
8. Quantitative prediction of macrolide drug-drug interaction potential from in vitro studies using testosterone as the human cytochrome P4503A substrate.
Polasek TM; Miners JO
Eur J Clin Pharmacol; 2006 Mar; 62(3):203-8. PubMed ID: 16416302
[TBL] [Abstract][Full Text] [Related]
9. Covalent alteration of the CYP3A4 active site: evidence for multiple substrate binding domains.
Schrag ML; Wienkers LC
Arch Biochem Biophys; 2001 Jul; 391(1):49-55. PubMed ID: 11414684
[TBL] [Abstract][Full Text] [Related]
10. Human cytochrome P-450 3A4: in vitro drug-drug interaction patterns are substrate-dependent.
Wang RW; Newton DJ; Liu N; Atkins WM; Lu AY
Drug Metab Dispos; 2000 Mar; 28(3):360-6. PubMed ID: 10681383
[TBL] [Abstract][Full Text] [Related]
11. In vitro metabolism of the calmodulin antagonist DY-9760e (3-[2-[4-(3-chloro-2-methylphenyl)-1-piperazinyl]ethyl]-5,6-dimethoxy-1-(4-imidazolylmethyl)-1H-indazole dihydrochloride 3.5 hydrate) by human liver microsomes: involvement of cytochromes p450 in atypical kinetics and potential drug interactions.
Tachibana S; Fujimaki Y; Yokoyama H; Okazaki O; Sudo K
Drug Metab Dispos; 2005 Nov; 33(11):1628-36. PubMed ID: 16049129
[TBL] [Abstract][Full Text] [Related]
12. In vivo CYP3A4 heteroactivation is a possible mechanism for the drug interaction between felbamate and carbamazepine.
Egnell AC; Houston B; Boyer S
J Pharmacol Exp Ther; 2003 Jun; 305(3):1251-62. PubMed ID: 12606595
[TBL] [Abstract][Full Text] [Related]
13. Prediction of in vivo drug-drug interactions from in vitro data : factors affecting prototypic drug-drug interactions involving CYP2C9, CYP2D6 and CYP3A4.
Brown HS; Galetin A; Hallifax D; Houston JB
Clin Pharmacokinet; 2006; 45(10):1035-50. PubMed ID: 16984215
[TBL] [Abstract][Full Text] [Related]
14. Atypical cytochrome p450 kinetics: implications for drug discovery.
Tracy TS
Drugs R D; 2006; 7(6):349-63. PubMed ID: 17073518
[TBL] [Abstract][Full Text] [Related]
15. Testosterone, 7-benzyloxyquinoline, and 7-benzyloxy-4-trifluoromethyl-coumarin bind to different domains within the active site of cytochrome P450 3A4.
Lu P; Lin Y; Rodrigues AD; Rushmore TH; Baillie TA; Shou M
Drug Metab Dispos; 2001 Nov; 29(11):1473-9. PubMed ID: 11602524
[TBL] [Abstract][Full Text] [Related]
16. Sigmoidal kinetics of CYP3A substrates: an approach for scaling dextromethorphan metabolism in hepatic microsomes and isolated hepatocytes to predict in vivo clearance in rat.
Witherow LE; Houston JB
J Pharmacol Exp Ther; 1999 Jul; 290(1):58-65. PubMed ID: 10381760
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of atypical cytochrome P450 kinetics with two-substrate models: evidence that multiple substrates can simultaneously bind to cytochrome P450 active sites.
Korzekwa KR; Krishnamachary N; Shou M; Ogai A; Parise RA; Rettie AE; Gonzalez FJ; Tracy TS
Biochemistry; 1998 Mar; 37(12):4137-47. PubMed ID: 9521735
[TBL] [Abstract][Full Text] [Related]
18. Enzyme kinetics of cytochrome P450-mediated reactions.
Shou M; Lin Y; Lu P; Tang C; Mei Q; Cui D; Tang W; Ngui JS; Lin CC; Singh R; Wong BK; Yergey JA; Lin JH; Pearson PG; Baillie TA; Rodrigues AD; Rushmore TH
Curr Drug Metab; 2001 Mar; 2(1):17-36. PubMed ID: 11465149
[TBL] [Abstract][Full Text] [Related]
19. The kinetics of aflatoxin B1 oxidation by human cDNA-expressed and human liver microsomal cytochromes P450 1A2 and 3A4.
Gallagher EP; Kunze KL; Stapleton PL; Eaton DL
Toxicol Appl Pharmacol; 1996 Dec; 141(2):595-606. PubMed ID: 8975785
[TBL] [Abstract][Full Text] [Related]
20. Metabolism of levo-alpha-Acetylmethadol (LAAM) by human liver cytochrome P450: involvement of CYP3A4 characterized by atypical kinetics with two binding sites.
Oda Y; Kharasch ED
J Pharmacol Exp Ther; 2001 Apr; 297(1):410-22. PubMed ID: 11259570
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
